190 related articles for article (PubMed ID: 38160415)
41. Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma.
van Dijken BRJ; Ankrah AO; Stormezand GN; Dierckx RAJO; Jan van Laar P; van der Hoorn A
PLoS One; 2022; 17(2):e0264387. PubMed ID: 35213602
[TBL] [Abstract][Full Text] [Related]
42. Clinical application of combination [
Wang Z; Feng Z; Zhu D; Wang X; Chen J; Zhu Y; Wang H
BMC Endocr Disord; 2024 Feb; 24(1):19. PubMed ID: 38311763
[TBL] [Abstract][Full Text] [Related]
43. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours.
Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Fukumura T; Mihara F; Morioka T; Fukui M; Masuda K
Eur J Nucl Med; 1998 Sep; 25(9):1261-9. PubMed ID: 9724375
[TBL] [Abstract][Full Text] [Related]
44. Methionine-PET to differentiate between brain lesions appearing similar on conventional CT/MRI scans.
Ohmura K; Ikegame Y; Yano H; Shinoda J; Iwama T
J Neuroimaging; 2023; 33(5):837-844. PubMed ID: 37246342
[TBL] [Abstract][Full Text] [Related]
45. Clinical features and
Chen D; Zhu Y; Chen Y; Zhu D; Liu Z; Li T; Liu Y; Zhao K; Su X; Li L
BMC Infect Dis; 2022 Jul; 22(1):646. PubMed ID: 35896979
[TBL] [Abstract][Full Text] [Related]
46. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
[TBL] [Abstract][Full Text] [Related]
47. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
48. 11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment.
Tomura N; Saginoya T; Goto H
J Comput Assist Tomogr; 2018; 42(4):517-521. PubMed ID: 29613985
[TBL] [Abstract][Full Text] [Related]
49. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma.
Ahn SY; Kwon SY; Jung SH; Ahn JS; Yoo SW; Min JJ; Bom HS; Ki SY; Kim HJ; Lee JJ; Song SY; Yang DH
Clin Nucl Med; 2018 Aug; 43(8):e259-e264. PubMed ID: 29877882
[TBL] [Abstract][Full Text] [Related]
51. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by
Heidemeier A; Schloetelburg W; Thurner A; Metz C; Heidemeier H; Rasche L; Martin Kortuem K; Boeckle D; Weiland E; Benkert T; Nickel D; Werner R; Buck AK; Bley TA
Eur J Radiol; 2022 Oct; 155():110493. PubMed ID: 36027759
[TBL] [Abstract][Full Text] [Related]
52. Comparison of
Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
[TBL] [Abstract][Full Text] [Related]
53. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
54. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
[TBL] [Abstract][Full Text] [Related]
55. (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F]fluorodeoxyglucose and L-methyl-[(11)C]methionine PET.
Tateishi K; Tateishi U; Nakanowatari S; Ohtake M; Minamimoto R; Suenaga J; Murata H; Kubota K; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2014 Feb; 35(2):278-84. PubMed ID: 23928140
[TBL] [Abstract][Full Text] [Related]
56. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
57. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.
Gupta M; Gupta T; Purandare N; Rangarajan V; Puranik A; Moiyadi A; Shetty P; Epari S; Sahay A; Mahajan A; Janu A; Bagal B; Menon H; Kannan S; Krishnatry R; Sastri GJ; Jalali R
CNS Oncol; 2019 Dec; 8(4):CNS46. PubMed ID: 31779471
[No Abstract] [Full Text] [Related]
58. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.
Kim S; Chung JK; Im SH; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):52-9. PubMed ID: 15309332
[TBL] [Abstract][Full Text] [Related]
59. Correlation of
Mitamura K; Yamamoto Y; Norikane T; Hatakeyama T; Okada M; Nishiyama Y
Ann Nucl Med; 2018 Nov; 32(9):627-633. PubMed ID: 30032455
[TBL] [Abstract][Full Text] [Related]
60. A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images.
Wang K; Zhao X; Chen Q; Fan D; Qiao Z; Lin S; Jiang T; Dai J; Ai L
Medicine (Baltimore); 2017 Aug; 96(32):e7756. PubMed ID: 28796066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
